Reviewing Nobel Biocare (NBHGF) & Biomerica (BMRA)

Share on StockTwits

Nobel Biocare (OTCMKTS:NBHGF) and Biomerica (NASDAQ:BMRA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Risk & Volatility

Nobel Biocare has a beta of -0.24, suggesting that its stock price is 124% less volatile than the S&P 500. Comparatively, Biomerica has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.

Valuation & Earnings

This table compares Nobel Biocare and Biomerica’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nobel Biocare N/A N/A N/A N/A N/A
Biomerica $5.56 million 4.30 -$1.46 million ($0.17) -15.59

Nobel Biocare has higher earnings, but lower revenue than Biomerica.

Profitability

This table compares Nobel Biocare and Biomerica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nobel Biocare N/A N/A N/A
Biomerica -31.75% -41.73% -34.79%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Nobel Biocare and Biomerica, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nobel Biocare 0 0 0 0 N/A
Biomerica 0 0 1 0 3.00

Biomerica has a consensus price target of $7.50, suggesting a potential upside of 183.02%. Given Biomerica’s higher possible upside, analysts plainly believe Biomerica is more favorable than Nobel Biocare.

Insider & Institutional Ownership

1.5% of Biomerica shares are held by institutional investors. 26.8% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biomerica beats Nobel Biocare on 6 of the 9 factors compared between the two stocks.

Biomerica Company Profile

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive News & Ratings for Nobel Biocare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nobel Biocare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply